TrialLeukemia & lymphoma2019

A phase 2 study of alpha interferon for molecularly measurable residual disease in chronic myeloid leukemia after allogeneic hematopoietic cell transplantation.

Evandro D Bezerra et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.